跳至主要内容
临床试验/NCT03569072
NCT03569072已完成不适用

High Intensity Functional Image Guided Vmat Lung Evasion

Peter MacCallum Cancer Centre, Australia2 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2018年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
19
试验地点
2
主要终点
Treatment will be considered feasible if all of the following criteria is met: Reduction in mean functional lung dose of ≥2%, functional lung volume receiving 20Gy of ≥4%, Mean heart dose is ≤30 Gy and relative heart volume receiving 50 Gy is <25%

研究概览

简要总结

This study is being performed to assess the feasibility of adapting radiotherapy plans based on functional lung information and increasing the dose to the primary tumour. This is a single arm interventional pilot study involving 20 patients.

Aims Primary: to assess the feasibility of using ventilation and perfusion positron emission computed tomography (V/Q PET/CT) scans to adapt radiotherapy plans using Volumetric Modulated Arc Therapy (VMAT) to avoid regions of functional lung and deliver a higher dose to the primary tumour Secondary: to assess the incidence of acute and late radiotherapy toxicities, to quantify regional ventilation loss and regional perfusion loss on post treatment V/Q PET/CT, to assess associations of V/Q PET/CT with other functional lung imaging techniques, to assess overall survival, progression free survival and quality of life outcomes.

Participants: 20 patients stage IIIa-c non-small cell lung cancer for curative intent radiotherapy.

Methods: All patients will receive functional lung adapted 60 Gray (Gy) in 30 fractions to the primary and nodal planning target volume with a simultaneous integrated boost to the primary tumour to a total dose 69Gy in 30 fractions.

Expected outcomes: That functionally adapted lung radiotherapy using V/Q PET/CT imaging and VMAT planning is technically feasible.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years;
  • Written informed consent has been provided.
  • Histologically or cytologically confirmed Non-Small Cell Lung Cancer
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2 within 2 weeks prior to registration
  • Locally advanced disease (stage IIIA, IIIB, IIIC as per American Joint Committee on Cancer AJCC, 8th ed.) as confirmed on staging 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) PET/CT
  • No evidence of metastatic intracranial disease on CT brain with contrast or MRI
  • Willing to participate in the full follow up schedule
  • Planned for treatment with curative intent

排除标准

  • Participant is not able to tolerate supine position on PET/CT bed for the duration of the PET/CT acquisitions, is not cooperative, or needs continuous nursing (e.g. patient from Intensive Care Unit) or is unable to attend full course of follow up visits
  • Pregnancy or Breast-feeding
  • If history of a prior extra thoracic invasive malignancy (except non-melanomatous skin cancer) must be free from recurrence for a minimum of 3 years at the time of registration
  • Prior radiotherapy to the lungs or mediastinum (a history of prior breast radiotherapy is not an exclusion)
  • Prior known history of interstitial lung disease * A history of renal impairment or reaction to iodine contrast is not an exclusion criteria, if a patient has medical comorbidities that exclude the use of iodine contrasts, these exploratory investigations can be omitted.

结局指标

主要结局

Treatment will be considered feasible if all of the following criteria is met: Reduction in mean functional lung dose of ≥2%, functional lung volume receiving 20Gy of ≥4%, Mean heart dose is ≤30 Gy and relative heart volume receiving 50 Gy is <25%

时间窗: 1 year

To assess the technical feasibility of the delivery of personalised functional lung radiotherapy.

次要结局

  • Quantitative voxel-wise comparison of dual energy CT (DECT) iodine mapping with Perfusion PET/CT(3 months and 12 months following completion of radiotherapy)
  • The number of patients with Grade ≥ 2 cardiac toxicity will be assessed and graded using CTCAE v4.03.(3 months and 12 months following completion of radiotherapy)
  • Quantitative voxel-wise comparison of perfusion PET/CT measures will be contoured using semi-automatic threshold based on the operator's discretion and compared with the pre-treatment perfusion PET/CT.(3 months and 12 months following completion of radiotherapy)
  • The number of patients with radiation pneumonitis will be assessed and graded using CTCAE v4.03(1 year)
  • Quantitative voxel-wise comparison of ventilation PET/CT measures will be contoured using semi-automatic threshold based on the operator's discretion and compared with the pre-treatment ventilation PET/CT.(3 months and 12 months following completion of radiotherapy)
  • Quantitative voxel-wise comparison of CT Ventilation with Ventilation PET/CT(3 months and 12 months following completion of radiotherapy)

研究者

发起方
Peter MacCallum Cancer Centre, Australia
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验